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Summary
  Haematopoietic stem cell transplantation (HSCT) is a therapeutic modality used 
in anti-tumour treatment of haematological malignancies as well as solid tumours. 
Apart from that it is also used in therapy of non-malignant and hereditary diseas-
es. As well as all the other treatments, HSCT also affects the disease process and 
with that also the patient’s quality of life (QoL). In the last decade of the 20th cen-
tury several studies about QoL in patients after HSCT were undertaken and the 
inﬂ uence in particular dimensions of QoL was observed. One of the closely ob-
served aspects was sexuality in patients after HSCT. Sexuality and its expression 
is a very important aspect of human behaviour. It is also a very sensitive aspect, 
so without doubt it is affected by diagnosis of neoplasm and cancer treatment. 
Physical and psychosocial factors of HSCT affect patients’ sexuality and sexual 
functioning, and with that also their QoL. They remain in focus because of the 
complex care concerning patients after HSCT.
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BACKGROUND
Haematopoietic stem cell transplantation 
(HSCT) is a therapeutic modality used in anti-
tumour treatment of haematological malignan-
cies as well as solid tumours. Apart from that it 
is also used in therapy of non-malignant and 
hereditary diseases [1]. The process of HSCT 
is for the patient quite challenging, for several 
reasons. First of all there are unwanted effects 
of systematic chemotherapy, and repetitive inva-
sive performances – central and peripheral vein 
catheterization, diagnostic aspiration of bone 
marrow, and so on. In men there is also sperm 
taking followed by cryoconservation of seminal 
ﬂ uid because of the possibility of reproductive 
organ dysfunction caused by intensive anti-tu-
mour therapy (permanent or temporary infer-
tility). Hormone replacement therapy is indicat-
ed in young females, because of the possibility 
of damaging the reproductive organs. Also we 
have to consider several weeks’ isolation in a 
sterile box. There is increased sensibility to op-
portunistic infections (bacterial, viral, fungal, 
mycoplasmatic, etc.) as an effect of bone mar-
row toxicity caused by high-dose chemotherapy. 
Besides those symptoms, the patient is loaded 
with the results of toxicity caused by high dose 
chemotherapy (mucositis, gastroenteritis, der-
matitis, alveolitis, signs of cardiotoxicity and 
neurotoxicity). A serious complication is acute 
or chronic graft-versus-host disease (GVHD), 
which is the result of allogeneic transplanta-
tion (from a relative or non-relative donor). 
Acute GVHD affects especially the liver, muco-
sa of the intestinal tract and skin. Serious forms 
can cause death. Chronic GVHD damages par-
ticularly the intestinal tract and skin and can 
handicap the patient. When listing all possible 
risks and complications it is necessary to men-
tion that in high-dose chemotherapy followed 
by HSCT it cannot be guaranteed 100% that 
all malignant cells will be eliminated. There is 
a possibility of relapse and as an optional treat-
ment we can again choose high dose chemo-
therapy followed by HSCT [1].
As well as all the other treatments HSCT also af-
fects the disease process and with that also the 
patient’s quality of life (QoL) (see Figure 1). In 
the last decade of the 20th century several stud-
ies on QoL in patients after HSCT were under-
taken and the inﬂ uence on particular dimen-
sions of QoL was observed. One of the closely 
observed aspects was sexuality in patients after 
HSCT (see Figure 2).
SEXUALITY, SEXUAL MOTIVATION, SEXUAL DYSFUNCTION
Sexual health is deﬁ ned by the World Health 
Organization as “a state of physical, emotional, 
mental and social well-being related to sexuali-
ty; not merely the absence of disease, dysfunc-
tion or inﬁ rmity”. All those aspects enrich and 
advance personality, communication and love 
of humans [2].
Human sexual behaviour is the result of a long 
evolutionary process, and therefore behaviour 
that human beings use when seeking sexual or 
relational partners, gaining approval of possible 
partners, forming relationships, showing affec-
tion and mating. It could be quite imperative, to 
some extent not depending on rational control 
mechanisms [3]. For didactic reasons we suggest 
considering 4 components of human sexuality, 
which are [4]: 1. sexual identity (sexual role), 2. 
sexual orientation (erotic preference), 3. sexu-
al emotion (sexual excitement, orgasm, love), 4. 
sexual behaviour. Sexual identity based on sex-
ual orientation is the headstone for sexual mo-
tivation. The sign of sexual identity is the abili-
ty of individuals to take a corresponding social 
role. The basic dimorphism in sexual orientation 
results from the principle of bisexual differenti-
ation. Normal sexual orientation means that it 
is related to a sexual mature person of the op-
posite sex. Sexual emotions include: sexuality, 
sensational peak (orgasm) and emotion of love 
(erotic fascination). Sexual behaviour has a ten-
dency to form a pair. A sexual pair tends to stick 
together and shows restriction in sexual behav-
iour to the other member of the unit. In a well 
functioning pair sexuality is experienced more 
naturally and more intensively [4].
Sexual dysfunctions are known as quantitative 
disorders of sexual performance [3]. The behav-
iourist conception of sexual dysfunctions results 
from the conception of four basic components 
of human sexual behaviour [3,4]: 1. sexual appe-
tite, 2. sexuality, 3. orgasm, 4. sexual satisfaction. 
Aetiology of sexual dysfunctions is multiplex, and 
is composed of constitutional, biological, psycho-
logical and social factors [3,4].
CHANGES IN SEXUALITY OF MEN TREATED BY MEANS OF 
HSCT AND INFLUENCE OF HSCT ON QOL
Diagnosis of malignity, subsequent treatment with 
high dose chemotherapy followed by HSCT and 
its complications and their treatment, all accord-
ing to Ferrell [7] can lead to changes in a patient’s 
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sexual life, particularly in accordance with sexual 
dysfunctions and sexual frustration. Sexual dysfunc-
tions and sexual frustration are often mentioned 
as factors which negatively inﬂ uence QoL in pa-
tients after HSCT [9,10]. According to Marks [11], 
Molassiotis [12,13] and Schubert [14], loss of de-
sire for sex, ejaculation disorders, erectile dysfunc-
tion and infertility are the most common sexual 
problems in men after HSCT. Incidence of sexual 
dysfunctions or dissatisfaction in men after HSCT 
is high, as evidenced by the results of Andersen’s 
study [15]. The study observed sexual dysfunc-
tions in more than 90% of patients with neopla-
sia. Wigard’s [16] and Chiodi’s [17] study shows 
22–70% of patients after HSCT with sexual dysfunc-
tions. Watson [18] noticed deterioration in sexual 
life in 55% of patients after allogenic HSCT and in 
42% of patients after autologous HSCT.
PHYSICAL AND PSYCHOLOGICAL ASPECTS AFFECTING 
THE MALE SEXUAL CONDITION AFTER HSCT
Physical and biological changes in males after 
HSCT treatment are determined by gonadal 
function and hypothalamo-pituitary-gonadal axis 
[19] (see Figure 3).
The secretion of testosterone from Leydig cells 
of the testis is controlled by luteinizing hor-
mone of hypophysis. Follicle stimulating hor-
mone stimulates spermatogenesis and it corre-
lates with creation of another hormone of the 
testis, inhibin. Inhibin correlates a way of nega-
tive reverse phrase.
Quality of life, QoL
Dimension of QoL
Aspects of QoL
Physical
Health status (subjective aspect) Functional status (objective aspect)
Social SpiritualPsychological
Life satisfaction
Figure 1. Dimensions of QoL [1]. The QoL term 
contains information on an individual’s physical, 
psychological, social and spiritual condition.
Sexuality
Dimension of sexuality
Indicators of sexuality
Physical
Sexual functioning (objective)Sexual satisfaction (subjective)
Social SpiritualPsychological
Figure 2. Dimensions of sexuality with objective 
and subjective indicators [3,4].
 
Hypothalamus
Leyding cells
Testosterone Inhibin
Sertoli cells
Hypophysis
GnRH
FSHLH
Figure 3. Hypothalamo-pituitary-gonadal axis in man [19]. GnRH 
– gonadoliberins, LH – luteinization hormone, FSH – follicle 
stimulating hormone.
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Physiological changes include neurovascular dis-
orders, erectile dysfunction, ejaculation praecox 
and infertility [19,20]. Those changes could af-
fect negatively one or more phases of sexual mo-
tivation and at the same time could affect ad-
versely sexual behaviour and satisfaction. In the 
period of preparation before transplantation 
(often high dose chemotherapy with/without 
whole-body radiation) is deletion or reduction 
of male sexual hormone production, because of 
negative feedback absence [20]. Gonadal dys-
function and changes of endocrinal functions 
(defect at hypothalamo-pituitary-gonadal axis 
level) in men after HSCT lead to their infertility 
and potential changes in their sexual function-
ing [19]. Reduced response to gonadoliberins 
(GnRH) can in some men show a potential dys-
function at the hypothalamo-pituitary level [21]. 
Elevated serum levels of prolactin can in some 
men after HSCT point to a defect at the hypoth-
alamic level. Hyperprolactinemia is one of the 
reasons for infertility, erectile dysfunctions and 
loss of sexual desire in men after HSCT [21]. 
Grade of gonadal and endocrinal dysfunction 
is determined by age, intercurrent diseases, to-
tal dose of radiation, type of cytostatic schedule 
used in preparation before transplantation, and 
it is also determined by the type of HSCT (au-
tologous, allogeneic) [20,22]. High-dose alkyla-
tor and radiation therapy invariably affect tes-
ticular function. The degree and the duration 
of gonadal failure depend on the dose of radi-
ation therapy received and the age at which it 
is received. About 90% of prepubertal male pa-
tients undergo puberty normally and maintain 
testosterone levels in the reference range. The 
resistance of male gonads to chemotherapy and 
radiation therapy is a function of increased num-
bers of Sertoli cells in prepubertal boys compared 
with that in post-pubertal male adolescents and 
men. However, men may develop testosterone de-
ﬁ ciency. The decline in male gonadal function 
is less recognized than its counterpart in female 
patients, but is likely to involve medical and psy-
chosocial complications. Alkylating agents are of-
ten used in HSCT; their side effect is infertility 
[23]. External radiotherapy and chemotherapy 
damage germinal sexual cells and seminiferous 
tubules. The results of that are azoosperm, testic-
ular atrophy and infertility. Kaupilla’s [21] study 
from 1998 was concerned with long-term inﬂ u-
ence of allogeneic transplantation of steam cells 
on hypophysal, gonadal, thyroidal and epine-
phral function. One of the main results of this 
study is depletion of germinal sexual cells by men 
after HSCT, which is explained by small size of 
testes and reduction of testicular volume [21]. 
Kaupilla [21] tried to quantify those discrepan-
cies, so he showed that the average size of tes-
ticles in healthy men is 5x3cm compared to av-
erage size 3.7×2.3 in men after HSCT. He also 
makes a point about average testicular volume, 
which is 16–30cm3 in healthy men and 8–15cm3 
in men after HSCT. The other outcomes from this 
study are the changes of endocrinal production 
in men after HSCT; the serum values are (phys-
iological values are listed in parentheses): FSH 
(follicle-stimulating hormone) 25–90mIU/ml 
(4–25mIU/ml), LH (luteinizing hormone) 
8–25mIU/ml (4–20mIU/ml), testosterone 
200–700mg/100ml (250–1200mg/100ml), dai-
ly production of testosterone 3.5mg/per day 
(7.5mg per day), free testosterone 8.6ng/100ml 
(15.3ng/100ml) [21]. One of the negative ef-
fects on sexuality in men after HSCT is chronic 
GVHD according to Fiedner [24] and Muir [25]. 
Authors like Barton-Burke [26], Inder [27] and 
Toy [28] sympathize with this statement.
PSYCHOLOGICAL ASPECTS AFFECTING THE SEXUAL 
CONDITION IN MALES TREATED BY MEANS OF HSCT
Sexual motivation in patients after HSCT is neg-
atively affected by: changes in physical condi-
tion, changes of self-perception, depression, 
anxiety, weak self-conﬁ dence, somatisation, 
fear of relapse, anger, desperation and infertil-
ity [18,29]. Infertility plays an essential role in 
all psychological aspects, because it could be a 
cause of relationship disturbances, not only in 
the family, but also among friends and at work 
[18,30]. Psychological aspects like depression 
and anxiety could signiﬁ cantly inﬂ uence more 
than one phase of human sexual motivation. 
Higher incidence of sexual disorders was de-
scribed in men with a rigid perspective on sex-
uality, with restricted range of sexual behavior 
and also in men with pessimistic future out-
look [15,16].
SOCIAL SSPECTS AFFECTING THE SEXUAL CONDITION IN 
MALES TREATED BY MEANS OF HCT
The most important role from all social aspects 
is that of a faithful partner [9]. Negative effects 
in the social dimension of QoL could be caused 
by the partner’s insecurity, lability, anxiety, faith-
lessness and communication difﬁ culties during 
treatment. Social encouragement is important 
to the patient during and after HSCT. It also af-
fects psychosocial adaptation of the patient after 
HSCT [9,10,31].
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CONCLUSIONS
The dimensional module of QoL represents a 
multiple approach to a number of life aspects 
[1]. The effects of several aspects could vary, be-
cause they depend on the phase of the disease 
and treatment. These ﬁ ndings bring our knowl-
edge about the patients’ needs into a different 
perspective and so they could signiﬁ cantly con-
tribute to improvement of health care. They can 
also uncover mechanisms that modify disease or-
igin and process [1].
Sexuality is a closely observed aspect of QoL in 
patients after HSCT. Sexuality and its expression 
is a very important aspect of human behaviour. 
It is also a very sensitive aspect, so without doubt 
it is affected by diagnosis of neoplasm and can-
cer treatment [7]. Physical and psychosocial fac-
tors of HSCT affect patients’ sexuality and sexu-
al functioning, including QoL. They remain in 
focus because of the complex care concerning 
patients after HSCT [32].
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